Pluronic copolymer encapsulated SCR7 as a potential anticancer agent
Keyword(s):
Nonhomologous end joining (NHEJ) of DNA double strand breaks (DSBs) inside cells can be selectively inhibited by 5,6-bis-(benzylideneamino)-2-mercaptopyrimidin-4-ol (SCR7) which possesses anticancer properties. The hydrophobicity of SCR7 decreases its bioavailability which is a major setback in the utilization of this compound as a therapeutic agent. In order to circumvent the drawback of SCR7, we prepared a polymer encapsulated form of SCR7. The physical interaction of SCR7 and Pluronic® copolymer is evident from different analytical techniques. The in vitro cytotoxicity of the drug formulations is established using the MTT assay.
2005 ◽
Vol 25
(3)
◽
pp. 896-906
◽
Involvement of Artemis in nonhomologous end-joining during immunoglobulin class switch recombination
2008 ◽
Vol 205
(13)
◽
pp. 3031-3040
◽
2015 ◽
Vol 112
(3)
◽
pp. 773-778
◽
2003 ◽
Vol 159
(3)
◽
pp. 426-432
◽
Keyword(s):
Keyword(s):
Keyword(s):